Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
CEO: Helen Giza. Company website
Fresenius Medical Care AG & Co. KGaA (FMS) trades at $22.20, up 0.59% on the day, as of Sep 20, 2026 14:58 UTC.
Fresenius Medical Care AG & Co. KGaA has a market capitalisation of $11.92B, calculated from the live FMS share price and shares outstanding.
FMS trades at a trailing P/E of 13.37, from earnings per share of $1.66 over the last twelve months.
Fresenius Medical Care AG & Co. KGaA generated revenue of $19.43B over the trailing twelve months, which puts the stock at 0.61 times sales.
Yes. Fresenius Medical Care AG & Co. KGaA pays a dividend yielding 3.86% on the current share price.
FMS has traded between $20.02 and $27.64 over the past 52 weeks, and the last price is 19.7% below that high.
Yes. Fresenius Medical Care AG & Co. KGaA keeps 4.83% of revenue as net income over the trailing twelve months.
Wall Street analysts rate FMS Hold, with an average price target of $23.57, 6.2% above the current price.
Fresenius Medical Care AG & Co. KGaA is classified under the Healthcare sector and the Medical - Care Facilities industry, and is domiciled in DE.
Helen Giza is the chief executive of Fresenius Medical Care AG & Co. KGaA, which employs 108,165 people.
QFI Terminal shows FMS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FMS in Terminal See plans